Asensus Surgical, Inc. (ASXC)

Market Cap	189.47M
Revenue (ttm)	7.10M
Net Income (ttm)	-73.55M
Shares Out	236.84M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,061,414
Open	0.820
Previous Close	0.821
Day's Range	0.790 - 0.840
52-Week Range	0.280 - 0.930
Beta	1.38
Analysts	Buy
Price Target	2.30 (+187.5%)
Earnings Date	Feb 27, 2023

About ASXC

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 153
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: ASXC

Financial Performance

In 2021, ASXC's revenue was $8.23 million, an increase of 159.28% compared to the previous year's $3.18 million. Losses were -$62.46 million, 4.06% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for ASXC stock is "Buy." The 12-month stock price forecast is $2.3, which is an increase of 187.50% from the latest price.

Price Target

$2.3

(187.50% upside)

Analyst Consensus: Buy